Goldman Sachs’s SpyGlass Pharma SGP Stock Holding History

Goldman Sachs’s Portfolio SGP Stock Details SGP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,283	Closed	-$500K	–	7209
2026 Q1	$500K	Buy	+19,283	New	+$519K	﹤0.01%	5596

Other funds holding SGP

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs's SGP Position: Q2 2026 in Review

Goldman Sachs sold out of SpyGlass Pharma (SGP) in Q2 2026, closing a stake of 19,283 shares — an estimated $500K sold.

Goldman Sachs first reported a position in SGP in Q1 2026 and held it in 1 quarter. The position peaked at $500K in Q1 2026. 52 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

Goldman Sachs reported no remaining SpyGlass Pharma position as of Q2 2026 after selling out during the quarter.
Goldman Sachs sold 19,283 SpyGlass Pharma shares in Q2 2026, an estimated $500K.
Goldman Sachs first reported a position in SpyGlass Pharma in Q1 2026 and held it in 1 quarter.
Goldman Sachs's SpyGlass Pharma position peaked at $500K in Q1 2026.
52 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.